AbbVie Inc. Operating Income

Operating Income of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending December 30, 2019 was $3.96 Billion (a 51.17% increase compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 31.43%
  • Annual Operating Income for 2019 was $13 Billion (a 103.4% increase from previous year)
  • Annual Operating Income for 2018 was $6.38 Billion (a -33.13% decrease from previous year)
  • Annual Operating Income for 2017 was $9.55 Billion (a 2.19% increase from previous year)
  • Twelve month Operating Income ending December 30, 2019 was $13 Billion (a 97.13% increase compared to previous quarter)
  • Twelve month trailing Operating Income increased by 100.05% year-over-year
Trailing Operating Income for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$13 Billion $6.59 Billion $7.13 Billion $6.49 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of AbbVie Inc.

Most recent Operating Incomeof ABBV including historical data for past 10 years.

Interactive Chart of Operating Income of AbbVie Inc.

AbbVie Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $3,956.0 $2,617.0 $3,400.0 $3,010.0 $12,983.0
2018 $-2,441.0 $3,159.0 $2,762.0 $2,903.0 $6,383.0
2017 $1,782.0 $2,694.0 $2,662.0 $2,407.0 $9,545.0
2016 $2,314.0 $2,361.0 $2,387.0 $2,278.0 $9,340.0
2015 $2,113.0 $1,885.0 $1,852.0 $1,687.0 $7,537.0
2014 $-415.0 $960.0 $1,515.0 $1,351.0 $3,411.0
2013 $1,535.0 $1,371.0 $1,453.0 $1,305.0 $5,664.0
2012 $1,821.0 $1,596.0 $1,422.0 $978.0 $5,817.0
2011 $-5,886.69 $4,409.0 $4,274.0 $824.44 $3,620.0
2010 $4,717.0
2009 $4,931.79

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.